Insmed Announces Pricing of Public Offering of Common Stock
06 sept. 2017 21h36 HE
|
Insmed Incorporated
BRIDGEWATER, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced an offering of 12,281,000 shares of its common stock in a registered...
Insmed Announces Proposed Public Offering of Common Stock
05 sept. 2017 16h01 HE
|
Insmed Incorporated
BRIDGEWATER, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $250 million of shares of its common...
Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
05 sept. 2017 07h00 HE
|
Insmed Incorporated
Study met primary endpoint of culture conversion (p< 0.0001)Positive top-line results from global Phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection...
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
03 août 2017 07h30 HE
|
Insmed Incorporated
On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis...
Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
27 juil. 2017 08h00 HE
|
Insmed Incorporated
BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed to Host Analyst and Investor Day on July 19, 2017
12 juil. 2017 08h00 HE
|
Insmed Incorporated
BRIDGEWATER, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today...
Insmed to Present at the JMP Securities Life Sciences Conference
13 juin 2017 08h00 HE
|
Insmed Incorporated
BRIDGEWATER, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08 juin 2017 08h00 HE
|
Insmed Incorporated
BRIDGEWATER, N.J., June 08, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Announces Key Additions to its Executive Management Team
15 mai 2017 07h00 HE
|
Insmed Incorporated
-- Paolo Tombesi named as Chief Financial Officer ---- Paul Streck, M.D., appointed as Chief Medical Officer ---- Eugene Sullivan, M.D., assumes role of Chief Product Strategy Officer --BRIDGEWATER,...
Insmed Reports First Quarter 2017 Financial Results and Provides Business Update
03 mai 2017 08h02 HE
|
Insmed Incorporated
Advancing Toward Top-Line Results from CONVERT Study in 2H 2017 Conference call today at 8:30 AM ET BRIDGEWATER, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM),...